How can insulin initiation delivery in a dual-sector health system be optimised? A qualitative study on healthcare professionals' views

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Lee, Ping Yein ^a   Lee, Yew Kong ^b   Ng, Chirk Jenn ^b  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Diabetes; Dual sector health system; Insulin initiation; Malaysia; Private sector; Public sector

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG INDUSTRY; EDUCATION; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MALAYSIA; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PUBLIC-PRIVATE PARTNERSHIP; QUALITATIVE RESEARCH; STANDARD;

ADULT; AGED; DIABETES MELLITUS; DRUG INDUSTRY; FEMALE; HEALTH PERSONNEL; HEALTH PROMOTION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALAYSIA; MALE; MIDDLE AGED; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; QUALITATIVE RESEARCH; QUALITY ASSURANCE, HEALTH CARE;

EID: 84862205758     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-313     Document Type: Article

References (47)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 9131 837 853 9742976
2. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. DeWitt DE, Hirsch IB, JAMA 2003 289 17 2254 2264 10.1001/jama.289.17.2254 12734137 (Pubitemid 37430194)
3. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, Rawdaree P, Plengvidhya N, Leelawatana R, Bunnag P, Pratipanawatr T, Krittiyawong S, Suwanwalaikorn S, et al. J Med Assoc Thai 2006 89 Suppl 1 66 71 17715836
4. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Liebl A, Mata M, Eschwege E, Diabetologia 2002 45 7 23 28 12136408
5. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, Gliwa A, Von Gizycki H, Sowers JR, Diabetes Care 2002 25 4 718 723 10.2337/diacare.25.4.718 11919131 (Pubitemid 41071193)
6. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S, Clin Ther 2006 28 3 388 395 10.1016/j.clinthera. 2006.03.005 16750453 (Pubitemid 44208781)
7. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S, Diabet Med 2005 22 10 1420 1426 10.1111/j.1464-5491.2005.01648.x 16176206 (Pubitemid 41391321)
8. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO, Diabetes Care 2004 27 1 17 20 10.2337/diacare.27.1.17 14693960 (Pubitemid 38196703)
9. Global burden: prevalence and projections, 2010 and 2030. [ http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance ]
10. International Diabetes Federation Atlas- 5th Edition, Diabetes Estimates, Diabetes Prevalence comparative 2011. [ http://www.idf.org/atlasmap/atlasmap ]
11. Control and treatment profiles of 70,889 adult type 2 diabetes mellitus patients in Malaysia-a cross sectional survey in 2009. Ismail M, Chew BH, Lee PY, Cheong AT, Shariff GS, Haniff J, Syed Abdul Rahman SA, Taher SW, Ahmad Z, Int J Collaborative Res Internal Med Pu Health 2011 3 98 113
12. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study. Donnan PT, Steinke DT, Newton RW, Morris AD, Diabet Med 2002 19 7 606 610 10.1046/j.1464-5491.2002.00743.x 12099966 (Pubitemid 35300684)
13. Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006. Letchuman GR, Wan Nazaimoon WM, Wan Mohamad WB, Chandran LR, Tee GH, Jamaiyah H, Isa MR, Zanariah H, Fatanah I, Ahmad Faudzi Y, Med J Malaysia 2010 65 3 180 186 21939164
14. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. Haque M, Emerson SH, Dennison CR, Navsa M, Levitt NS, S Afr Med J 2005 95 10 798 802 16341336 (Pubitemid 41601169)
15. Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. Pope C, Mays N, BMJ 1995 311 6996 42 45 10.1136/bmj.311.6996.42 7613329
16. Bogdan R, Taylor SJ, Introduction to qualitative research methods New York: John Wiley 1975
17. Patton MQ, Qualitative evaluation methods Newbury Park, CA: Sage 1980
18. Qualitative research. Introducing focus groups. Kitzinger J, BMJ 1995 311 7000 299 302 10.1136/bmj.311.7000.299 7633241
19. A qualitative study on healthcare professionals' perceived barriers to insulin initiation in a multi-ethnic population. Lee YK, Lee PY, Ng CJ, BMC Fam Pract 2012 13 1 28 10.1186/1471-2296-13-28 22469132
20. Planning and Development Division, Health facts 2009: Information and Documentation System Unit Putrajaya: Ministry of Health Malaysia 2010
21. Family Health Development Division, Family Health Development Division statistic 2009 Putrajaya: Ministry of Health Malaysia 2009
22. National Institute of Health, National Health Care Establishment and Workforce Statistics 2008-2009 Putrajaya: Clinical Research Centre, National Institute of Health, Ministry of Health Malaysia 2010
23. Integrated Health services- What and Why, Making Health System Work Technical Brief No.1, May 2008 Geneva: World Health Organization 2008 [ http://www.who.int/healthsystems/technical-brief-final.pdf ]
24. Public-private collaboration in health and human service delivery: evidence from community partnerships. Bazzoli GJ, Stein R, Alexander JA, Conrad DA, Sofaer S, Shortell SM, Milbank Q 1997 75 4 533 561 10.1111/1468-0009.00068 9415091 (Pubitemid 127458352)
25. The Economic Planning Unit, 9th Malaysian Plan-2006-2010 Putrajaya: Prime Minister's Department of Malaysia 2006
26. Western Pacific Country Health Information Profiles, 2011: World Health Organization, Geneva 2011 192 200 [ http://www.wpro.who.int/countries/mys/ 15MAApro2011-finaldraft.pdf ]
27. Safurah J, One care for one Malaysia: Why and How. Abstract of Plenary lecture In 15th Malaysian Family Medicine Scientific Conference: 23-26 June 2011; Seremban, Negeri Sembilan, Malaysia. 2011
28. Angell M, The truth about the drug companies: how they deceive us and what to do about it New York: Random House 2004
29. Moynihan R, Cassells A, Selling sickness: how the drug companies are turning us all into patients Sydney: Allen & Unwin 2005
30. Jl C, The constant gardener New York: Simon and Schuster 2001
31. Physicians and the pharmaceutical industry: is a gift ever just a gift? Wazana A, JAMA 2000 283 3 373 380 10.1001/jama.283.3.373 10647801 (Pubitemid 30051756)
32. Interactions between physicians and drug company representatives. Chren MM, Am J Med 1999 107 2 182 183 10460053
33. Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group. Shipp DH, Mallarkey G, Med J Aust 2009 190 8 406 407 19374609
34. The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. White AR, J Antimicrob Chemother 2008 62 Suppl 2 i3 14 18819978
35. Relationships between health professionals and industry: maintaining a delicate balance. Komesaroff PA, Aust Prescriber 2007 30 150 153 (Pubitemid 350232596)
36. The Endocrine Society Ethics Advisory Committee: ethical aspects of conflicts of interests, October 2003. Komesaroff PA, Bach MA, Danoff A, Grumbach MM, Kaplan S, Lakoski JM, Leitman D, Mellon S, Underwood LE, Leupen S, Endocrinology 2004 145 6 3032 3041 15140839
37. Guidelines for ethical relationships between physicians and industry. [ http://www.racp.edu.au ]
38. Ethics and pharmaceutical medicine-the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. BickestaffeI R, Brock P, Husson J-M, Rubin I, Bragman K, Paterson K, Sommerville A
39. Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry? Haines IE, Olver IN, Med J Aust 2008 189 5 263 266 18759722
40. Ethics and the pharmaceutical industry. Green S, Australas Psychiatry 2008 16 3 158 165 10.1080/10398560701842595 18568619 (Pubitemid 351890606)
41. Consumer perceptions of sponsors of disease awareness advertising. Danika VH, Jones SC, Iverson DC, Health Education 2011 111 1 5 19
42. Working together. The guide. A guide to relationships between health consumer organisations and pharmaceutical companies. Revised Edition 2008. [ http://www.chf.org.au/pdfs/pos/pos-497-working-together-guide-manual-2008.pdf ]
43. Improving diabetes care: the model for health care reform. Kahn R, Anderson JE, Diabetes Care 2009 32 6 1115 1118 10.2337/dc09-0184 19460917
44. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B, Int J Clin Pract 2005 59 11 1345 1355 10.1111/j.1742-1241.2005.00674.x 16236091
45. The use of a multidisciplinary team care approach to improve glycemic control and quality of life by the prevention of complications among diabetic patients. Codispoti C, Douglas MR, McCallister T, Zuniga A, J Okla State Med Assoc 2004 97 5 201 204 15212108
46. A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA). Gagliardino JJ, Etchegoyen G, Diabetes Care 2001 24 6 1001 1007 10.2337/diacare.24.6.1001 11375360 (Pubitemid 33716366)
47. Building cultural bridges: understanding ethnicity to improve acceptance of insulin therapy in patients with type 2 diabetes. Caballero AE, Ethn Dis 2006 16 2 559 568 17682263 (Pubitemid 46952661)